Mind & sleep

DSIP

Delta sleep-inducing peptide

Studied forSleep and insomnia1 2

Community reportsSleep5

No FDA-approved DSIP/emideltide product identified.

What does it do?

Sleep-associated nonapeptide investigated for sleep, stress and pain; dependable clinical benefit remains uncertain.

Approved & studied uses

Sleep and insomnia research

1 2

Small historical controlled studies measured sleep; the insomnia result was weak.

Community uses Reported, unvalidated

Sleep

Source claims deeper sleep, easier onset and fewer awakenings.

Mood and stress

Reported anxiety, cortisol and mood effects.

Pain, hormones and withdrawal

Small historical studies; not established treatment.

Neurological recovery

Nasal stroke-recovery claims derive from animal models.

Reasons people report using it; these do not establish benefit.15

Evidence limits

View research →

Whether contemporary, adequately powered trials would show meaningful insomnia benefit.1

4 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Route-specific safety gap

FDA did not identify safety information for the proposed compounded route.3

No FDA-approved DSIP/emideltide product identified.

Molecular information

Amino-acid sequence

9 residues · N → C7

Length9 amino acids

Molecular weight · Da848.8 Da

Formula, sequence notation & identity

Molecular formulaC₃₅H₄₈N₁₀O₁₅7

W–A–G–G–D–A–S–G–E

Emideltide / delta sleep-inducing peptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.

Values refer to the parent peptide; the manufacturer sheet describes acetate material with additional counterion mass.

Pharmacokinetics

How long does it stay in the body?

Unverified reference estimateNot independently confirmed

Reference half-life8 min14

Route / formulationSource page: Injectable. Exact PK route not verified.

This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.

Elapsed time 8 min

50%of reference level

Illustrative scenario using an unverified reference estimate.

About 3% remaining after 40 min

Five half-lives in this estimated model. This is not a prediction of when effects stop.

Evidence and model details

Population: Not established by the reference estimate

Source’s stated attribution: Graf et al.

Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.

100 × 2^{−time / half-life}. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Weak insomnia results

The 16-person study found small objective changes and no subjective sleep-quality benefit; its authors considered a major therapeutic effect unlikely.2

Reported timelines

Reference & community

First night; nasal 15–45 min

Source-reported sleepiness.15

Days 2–10; nasal weeks 1–2

Reported sleep, energy and mood changes.15

After stopping: 1–2 weeks

Claimed persistence unverified.15

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Primary goal

General wellness26%

Other: Sleep16%

Recovery/Healing14%

Other: Better sleep6%

Cognitive enhancement4%

The source hides 31 additional categories. Their labels and percentages are unavailable.

Number of responses to this question: not disclosed.

Source & limitations

The source displays “1578 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Source corrections

Interaction categories are Pep-Pedia claims, not tested safety findings.

Route

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
IVIntravenous	25 nmol/kg	Afternoon administration before each of 3 consecutive nights	Assess chronic-insomnia sleep outcomesHuman study	3 nights	2
Population 16 chronic-insomnia patients, randomized DSIP versus placebo Context Historical controlled study; findings did not support a major therapeutic effect.
IVIntravenous	25 nmol/kg	Single dose in randomized crossover sessions	Acute endocrine responseHuman study	Acute observation	4
Population 11 healthy men aged 25–39 Context Saline-controlled hormone study; not an insomnia treatment protocol.
SubQ	100-200 mcg	Once nightly	Sleep EnhancementReference report	5-10 consecutive days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable
SubQSubcutaneous	250-300 mcg	Daily	Chronic PainReference report	5-10 consecutive days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source route wording IV or SubQ Source tabs Injectable
IVIntravenous	250-300 mcg	Daily	Chronic PainReference report	5-10 consecutive days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source route wording IV or SubQ Source tabs Injectable
SubQ	150 mcg	Evening	Stress ManagementReference report	5-10 consecutive days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable
IVIV preferred	200-300 mcg	Twice daily	Withdrawal SupportReference report	5-10 consecutive days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable
SubQ	100-150 mcg	Post-training	Athletic RecoveryReference report	5-10 consecutive days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Injectable
IntranasalNasal spray	200-300 mcg	Once at bedtime	Sleep InductionReference report	7-14 days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Nasal
IntranasalNasal spray	150-200 mcg	Twice daily	Stress ReliefReference report	7-14 days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Nasal
IntranasalNasal spray	300-400 mcg	Daily	NeuroprotectionReference report	7-14 days	15
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction categories are Pep-Pedia claims, not tested safety findings. Source tabs Nasal

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports15

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period: 5-10 consecutive days
Break: 2-4 weeks between cycles

Reported timing

Evening administration 30-60 minutes before intended sleep

Nasal

Use period: 7-14 days
Break: 2-3 weeks between cycles

Reported timing

30 minutes before intended sleep or as needed for stress

Side effects & safety

Route-specific safety gap

FDA did not identify safety information for the proposed compounded route.

Immune and impurity concerns

FDA identifies possible immunogenicity and difficulty characterizing peptide impurities.

Limited study size

Sixteen insomnia patients provide little ability to detect uncommon or long-term adverse effects.

Additional reported cautions

Reference reports15

Sedation and headache

Drowsiness, dizziness, headache; assess impairment before driving.

Stop symptoms

Excess sedation, agitation/insomnia, mood deterioration, distressing dreams or allergy.

Nasal route

Irritation, bleeding, sinus pain/infection; congestion changes absorption.

Pregnancy and long-term safety

Not established; source reassurance about dependence is not proof.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

9 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

GABA agonists

Caution reported

Possible additive sedation.15

Reference report · Pep-Pedia label: Monitor Combination

Opioid medications

Caution reported

Uncertain opioid-pathway interaction.15

Reference report · Pep-Pedia label: Use Caution

Melatonin

Unverified pairing

Proposed sleep complement.15

Reference report · Pep-Pedia label: Synergistic

Cortisol modulators

Unverified pairing

Proposed stress complement.15

Reference report · Pep-Pedia label: Compatible

Selank

Unverified pairing

Proposed anxiety/sleep complement.15

Reference report · Pep-Pedia label: Synergistic

Semax

Unverified pairing

Proposed daytime/nighttime pairing.15

Reference report · Pep-Pedia label: Compatible

Growth hormone peptides

Unverified pairing

Combination safety unestablished.15

Reference report · Pep-Pedia label: Compatible

Epitalon

Unverified pairing

Proposed circadian complement.15

Reference report · Pep-Pedia label: Synergistic

Sedatives, alcohol and other sleep agents

Not established

The cited insomnia study does not establish these combinations as safe. A sleep-related mechanism is not a clinical interaction study.2

Research context

Reconstitution calculator

Enter your peptide amount and container size. Get a volume and a simple measurement scale.

1How much peptide do you have?

Total labeled amount of DSIP.

2How much can your container hold?

Usable capacity of the destination vial or pen cartridge.

Measure with

1 dial unit = 0.01 mL on the documented V2 model. Confirm your pen’s scale.

Vial examples & blend contents DSIP

Peptide reference

Listed amounts are packaging examples. Check your actual label.

Suggested final volume mL

Estimated water to add≈ mL

For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.

1 pen unit (one dial step)=

Measurement scale Conversions, not recommended doses
Pen units	Amount	Volume

Other simple scales

Convert a specific amount

Enter an amount to calculate its volume and device setting.

Amount to measure

Measuring-tool capacity

Calculation & assumptions

The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.

The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.

V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗

Reconstitution

Laboratory handling only

A supplier sheet describes laboratory solubility, not a validated human injection preparation.7

Product-specific limits

The Cayman emideltide acetate sheet is for research material; its laboratory handling directions do not establish a bacteriostatic-water volume or injectable beyond-use date.7

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

Pep-Pedia provides a 1 mg/mL concentration example.

Solvents mentioned: Bacteriostatic water
Reported parameters: 1 mg in 1 mL; 100 mcg occupies 0.1 mL (10 U-100 syringe units). · Reported storage: refrigeration after mixing.

The source describes gentle mixing and avoiding vigorous shaking.

Nasal

The nasal section reports a 2 mg/mL solution and pump calibration.

Reported parameters: At 0.05 mL per spray, 2 mg/mL gives 100 mcg per spray. · The pump output is a stated assumption, not a universal nasal-spray volume.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite lyophilized powderReported appearanceClear solution when mixedReported variationShort stability periodReported concernYellow or cloudy solutionReported appearanceReputable source essentialReported variationProtect from degradation

Vial sizes

2mg6

5mg6

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.

Injectable

Unverified report15

14 days2–8°C

Full storage notes from Pep-Pedia

Injectable

Refrigerate at 2-8°C, protect from light, use within 14 days

Nasal

Refrigerate spray bottle, keep upright

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Pen & syringe measurements Scales, capacity & references

Pen & syringe measurements

Device units measure volume. Concentration determines the amount in mg.

Open calculator ↗

V2 peptide pen

1 notch = 0.01 mL

Documented 1-unit V2 models

One dial increment: 1 unit
Cartridge capacity: 3 mL
Maximum setting: 60 units · 0.60 mL

Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.

U-100 syringe

1 unit = 0.01 mL

100 units = 1 mL

10 units: 0.10 mL
30-unit capacity: 0.30 mL
50 / 100-unit capacity: 0.50 / 1 mL

Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.

Other measuring tools

Use the mL scale

mL syringes and calibrated pipettes

0.01 mL: 10 µL
0.10 mL: 100 µL
Amount: mL × mg/mL

Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.

3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.

Device references

AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.

Research findings

Limited human data

Source context

Interaction categories are Pep-Pedia claims, not tested safety findings.

Compound identity & other names

Delta sleep-inducing peptide has been tested in small sleep experiments. An early positive study was followed by weak results in chronic insomnia; the name should not be mistaken for a demonstrated treatment effect.

Other names: Delta sleep-inducing peptide · Emideltide · DSIP-9

No FDA-approved DSIP/emideltide product identified.

How it may work

Proposed GABA, NMDA, opioid and stress-axis modulation. Nasal brain targeting is a hypothesis, not proven comparative efficacy.15

An early sleep signal in six volunteers

A 1981 double-blind crossover study reported 59% higher median sleep time during a 130-minute window after an IV infusion. This was a very small acute experiment in healthy volunteers.

Little persuasive benefit in chronic insomnia

In a 1992 study of 16 patients, sleep efficiency and latency showed weak statistical improvements, possibly partly due to changes in the placebo group. Subjective sleep quality did not improve; investigators judged major short-term therapeutic benefit unlikely.

Endocrine change does not establish sleep benefit

Eleven healthy men showed lower ACTH-like immunoreactivity after IV DSIP, without a corresponding cortisol change. This endocrine experiment did not demonstrate a clinical sleep benefit.

Research areas and evidence gaps

Sleep and insomnia research. Small historical controlled studies measured sleep; the insomnia result was weak.1 2

Whether contemporary, adequately powered trials would show meaningful insomnia benefit.
Long-term safety and whether subcutaneous community schedules reproduce intravenous trial results.

Community reports Unvalidated

PepPedia describes improved deep sleep and easier sleep onset; its optimistic account should be read alongside the weak insomnia trial.5

PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations.

Search coverage and review status

No newer clinical paper was verified. Added an older controlled ACTH experiment without treating endocrine changes as a sleep benefit.

Checked: 2026-10-12
Search: "delta sleep inducing peptide" 2025 2026 study
Catalog: Pep-Pedia ↗ · 6 listed references retained

Targeted search and selected primary-source checks, not an exhaustive systematic review.
Preserved bibliography entries marked unreviewed have not had their findings independently verified.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

15 sources

1Acute and delayed effects of DSIP on human sleepTrial · 1981 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

A six-person crossover experiment found an acute sleep-time signal after intravenous DSIP; applicability to chronic insomnia is limited.

An early sleep signal in six volunteers

A 1981 double-blind crossover study reported 59% higher median sleep time during a 130-minute window after an IV infusion. This was a very small acute experiment in healthy volunteers.

Original source

2DSIP in chronic insomnia: double-blind studyTrial · 1992 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

In 16 patients, weak objective changes were not accompanied by subjective sleep-quality improvement; authors found major therapeutic benefit unlikely.

Little persuasive benefit in chronic insomnia

Original source

3FDA: compounding safety concernsRegulator · 2026 · fda.govPrimary source checked

AI-PREPARED SUMMARY

Regulatory safety assessment.

Original source

4Reduction of immunoreactive ACTH in plasma following intravenous administration of delta sleep-inducing peptide in manTrial · 1989 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

In a double-blind crossover study of 11 healthy men, intravenous DSIP lowered ACTH-like immunoreactivity for at least three hours, while measured cortisol outcomes were unchanged.

Endocrine change does not establish sleep benefit

Eleven healthy men showed lower ACTH-like immunoreactivity after IV DSIP, without a corresponding cortisol change. This endocrine experiment did not demonstrate a clinical sleep benefit.

Additional research · Checked 2026-10-12

Original source

5PepPedia: reported practices (accessed October 12, 2026)Community · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Secondary editorial account of discussed practices; not a clinical trial or representative survey.

Original source

6Research catalog: labeled quantitiesCatalog · 2026 · apexlab.orgCatalog checked

AI-PREPARED SUMMARY

Lists 2 mg and 5 mg powder-vial configurations. Quantity examples only; vendor quality and suitability are not endorsed.

Original source

7Cayman Chemical: Emideltide acetate product informationCatalog · 2026 · cdn.caymanchem.comCatalog checked

AI-PREPARED SUMMARY

Manufacturer chemistry sheet gives the nonapeptide identity, parent formula and 848.8 molecular weight; laboratory material, not human-use preparation instructions.

Original source

8Stroke Recovery in Rats (2021)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Rat motor recovery improved after stroke, while infarct size did not significantly change.

Reported population / model
Rats

Reported study details
120 μg/kg nasal · 7 days · Enhanced motor recovery

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

9Chronic Insomnia Double-Blind Study (1991)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: A small crossover insomnia study reportedly improved objective sleep efficiency and latency, with less convincing subjective benefit.

Reported population / model
Human

Reported study details
15-30 nmol · 6 consecutive nights · Improved sleep efficiency

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

10Endocrine Modulation Research (1988)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The source summarizes changes in ACTH, cortisol and GH across heterogeneous experiments; it does not define a consistent clinical effect.

Reported population / model
Human/Animal

Reported study details
Various doses · Multiple studies · Hormone regulation

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

11Chronic Pain Pilot Study (1984)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Six of seven participants reportedly had lower chronic pain and depressive symptoms in an uncontrolled pilot.

Reported population / model
Human

Reported study details
25 nmol IV · 10 days · 6/7 patients improved

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

12Alcohol and Opioid Withdrawal (1984)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Clinical reports describe better sleep and less anxiety during alcohol or opioid withdrawal; controlled effectiveness is not established by the card.

Reported population / model
Human

Reported study details
Variable doses · 5-10 days · Symptom reduction

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

13Sleep Pressure Induction Study (1983)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The source reports 59% more sleep during a 130-minute observation and better later sleep efficiency after an IV dose.

Reported population / model
Human

Reported study details
25 nmol/kg IV · Single dose · 59% sleep increase

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

14Pep-Pedia: DSIP — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Lists a half-life of 8 min and a peak time of 30 min. Stated attribution: Graf et al.. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source

15Pep-Pedia: DSIP — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source

What does it do?

Approved & studied uses

Sleep and insomnia research

Community uses Reported, unvalidated

Sleep

Mood and stress

Pain, hormones and withdrawal

Neurological recovery

Evidence limits

Key safety information

Route-specific safety gap

Molecular information

Amino-acid sequence

How long does it stay in the body?

What to expect

Study outcomes

Weak insomnia results

Reported timelines

First night; nasal 15–45 min

Days 2–10; nasal weeks 1–2

After stopping: 1–2 weeks

Experience

Duration of use

Age range

Gender

Primary goal

Effectiveness

Side effects

Dosage frequency

Would recommend

How discovered

Doses & schedules

Cycles & timing

Injectable

Reported timing

Nasal

Reported timing

Side effects & safety

Route-specific safety gap

Immune and impurity concerns

Limited study size

Additional reported cautions

Sedation and headache

Stop symptoms

Nasal route

Pregnancy and long-term safety

Combinations & interactions

GABA agonists

Opioid medications

Melatonin

Cortisol modulators

Selank

Semax

Growth hormone peptides

Epitalon

Sedatives, alcohol and other sleep agents

Reconstitution calculator

Ingredients per unit

Reconstitution

Product-specific limits

Injectable

Nasal

Vial sizes

Storage after mixing

Reconstituted research vials

Injectable

Pen & syringe measurements

1 notch = 0.01 mL

1 unit = 0.01 mL

Use the mL scale

Research findings

Source context

An early sleep signal in six volunteers

Little persuasive benefit in chronic insomnia

Endocrine change does not establish sleep benefit

References

Related profiles